There are 3484 resources available
Invited Discussant 1312MO and 1313MO
Presenter: Lizza Hendriks
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Luis Paz-Ares
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Alison Schram
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Presenter: Li Zhang
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 1314MO, 1315MO and 1316MO
Presenter: Jordi Remon Masip
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Opening remarks & introduction
Presenter: All Speakers
Session: Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence
Resources:
Webcast
Introduction
Presenter: Michel Ducreux
Session: Servier - A journey through IDH1mutated Cholangiocarcinoma - Unveiling clinical and therapeutic perspectives
Resources:
Webcast
Welcome
Presenter: Vivek Subbiah
Session: Bayer - Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients’ Lives
Resources:
Webcast
Welcome and Introduction of Agenda and Speakers
Presenter: Charles Rudin
Session: Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer
Resources:
Webcast
How can we balance efficacy and QoL in mHSPC treatment? Why it’s time to tailor treatments
Presenter: All Speakers
Session: Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence
Resources:
Webcast